Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic…

LyGenesis, Inc., a biotechnology company developing innovative technology for organ regeneration, announced today that they have raised $3 million in Series A financing from Juvenescence, Ltd. LyGenesis’ technology uses lymph nodes as bioreactors to regrow functioning organs within a patient’s…

Wellist, the leading provider of Integrated Patient Experience Solutions, announced today that it had raised $10 million in Series A funding.┬áThe round was led by Summation Health Ventures, a strategic healthcare investment fund affiliated with MemorialCare Health System and Cedars-Sinai…